TREM1 and cancer: For example, Juric et al. demonstrated that the activation of triggering receptor expressed on myeloid cells 1(TREM-1) using the agonistic antibody PY159 could stimulate proinflammatory signaling pathways and enhance antitumor immunity in various cancer models, particularly through the reprogramming of TAMs and neutrophils into a proinflammatory state.23